Search research articles
Contact Us
Filters
Showing results (21-30 of 61) with videos related to
Page
of 7
Sort By:
American Heart Journal
|
June 16, 2019
Assessing cardiac safety in oncology drug development
Jonathan H Seltzer, Gary Gintant, Laleh Amiri-Kordestani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2016
Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis
Charles Guenancia, Annick Lefebvre, Daniela Cardinale, et al.
JAMA Oncology
|
October 15, 2020
Early Trastuzumab Interruption and Recurrence-Free Survival in ERBB2-Positive Breast Cancer
Robert S Copeland-Halperin, Mohammed Al-Sadawi, Sujata Patil, et al.
American Heart Journal
|
December 7, 2019
Corrigendum to "Assessing cardiac safety in oncology drug development" [Am Heart J 214 (2019) 125-133]
Jonathan H Seltzer, Gary Gintant, Laleh Amiri-Kordestani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 3, 2016
Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter
Chau T Dang, Anthony F Yu, Lee W Jones, et al.
JACC. Cardiooncology
|
October 26, 2020
Cardiotoxicity Surveillance and Risk of Heart Failure During HER2 Targeted Therapy
Anthony F Yu, Chaya S Moskowitz, Katherine Lee Chuy, et al.
Breast Cancer Research and Treatment
|
July 16, 2017
Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer
Anthony F Yu, Roy B Mukku, Shivani Verma, et al.
European Heart Journal. Imaging Methods and Practice
|
June 30, 2025
Long-term cardiovascular consequences of cancer therapy-related cardiac dysfunction: insights from ventricular-arterial coupling and myocardial work
Anthony F Yu, Jessica M Scott, Jessica Flynn, et al.
Breast Cancer Research and Treatment
|
January 2, 2015
Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer
Anthony F Yu, Nandini U Yadav, Betty Y Lung, et al.
Cardio-Oncology (London, England)
|
March 9, 2023
Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy
Anthony F Yu, Chau T Dang, Justine Jorgensen, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 61) with videos related to
Sort By:
Page
of 7
American Heart Journal
|
June 16, 2019
Assessing cardiac safety in oncology drug development
Jonathan H Seltzer, Gary Gintant, Laleh Amiri-Kordestani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2016
Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis
Charles Guenancia, Annick Lefebvre, Daniela Cardinale, et al.
JAMA Oncology
|
October 15, 2020
Early Trastuzumab Interruption and Recurrence-Free Survival in ERBB2-Positive Breast Cancer
Robert S Copeland-Halperin, Mohammed Al-Sadawi, Sujata Patil, et al.
American Heart Journal
|
December 7, 2019
Corrigendum to "Assessing cardiac safety in oncology drug development" [Am Heart J 214 (2019) 125-133]
Jonathan H Seltzer, Gary Gintant, Laleh Amiri-Kordestani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 3, 2016
Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter
Chau T Dang, Anthony F Yu, Lee W Jones, et al.
JACC. Cardiooncology
|
October 26, 2020
Cardiotoxicity Surveillance and Risk of Heart Failure During HER2 Targeted Therapy
Anthony F Yu, Chaya S Moskowitz, Katherine Lee Chuy, et al.
Breast Cancer Research and Treatment
|
July 16, 2017
Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer
Anthony F Yu, Roy B Mukku, Shivani Verma, et al.
European Heart Journal. Imaging Methods and Practice
|
June 30, 2025
Long-term cardiovascular consequences of cancer therapy-related cardiac dysfunction: insights from ventricular-arterial coupling and myocardial work
Anthony F Yu, Jessica M Scott, Jessica Flynn, et al.
Breast Cancer Research and Treatment
|
January 2, 2015
Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer
Anthony F Yu, Nandini U Yadav, Betty Y Lung, et al.
Cardio-Oncology (London, England)
|
March 9, 2023
Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy
Anthony F Yu, Chau T Dang, Justine Jorgensen, et al.
Page
of 7